MannKind FY Conference Summary Company Overview - **Company**: MannKind Corporation (NasdaqGM: MNKD) - **Date of Conference**: February 26, 2026 - **Key Speakers**: CEO Michael Costanja, CFO Chris Prentiss Financial Performance - **Total Revenues**: Nearly $350 million for FY 2025, representing a **46% annual growth rate** [2] - **Revenue Projection for 2026**: Expected to exceed **$450 million**, driven by several factors including pediatric expansion of Fariza and royalties from Tyvaso DPI [3] Product Development and Trials 1. **02/2001 for IPF** - **Phase One Study**: Initiated with 4 patients enrolled and 10 in screening, aiming for 12 total in the first cohort [6] - **Tolerability Focus**: The study aims to demonstrate the safety of a dry powder formulation in patients with Idiopathic Pulmonary Fibrosis (IPF) [10] - **Phase Two Study**: Expected to begin enrolling patients in Q2, focusing on higher doses and early efficacy [11][15] - **Market Potential**: 02/2001 is viewed as a potential blockbuster due to its tolerability compared to existing treatments [10] 2. **Inhale First Trial** - **Objective**: To transition children from injectable insulin to inhaled insulin post-hospital discharge [19] - **Titration Challenges**: Focus on understanding the logistics of insulin titration in naive patients [21] - **Patient Enrollment**: Initial sites have enrolled 3-4 patients out of 10 required to proceed [22] 3. **Fariza and Tyvaso** - **Pediatric Approval**: PDUFA date set for May 29, with expectations for increased awareness and adoption among pediatric endocrinologists [30] - **Market Awareness**: There is a lack of awareness about Afrezza among pediatric specialists, presenting a new market opportunity [32] Market Dynamics and Strategy - **Heart Failure and Chronic Kidney Disease**: MannKind is focusing on these areas as significant growth opportunities, particularly in hospital settings [38][44] - **Sales Strategy**: Investment in key account managers to penetrate hospital markets and improve product awareness [41] - **Product Lifecycle**: Introduction of ReadyFlow, an auto-injector, is expected to simplify administration and expand market reach [46][48] Stock Market Reaction - **Recent Stock Performance**: The stock experienced volatility following announcements related to UT's product developments, which were misinterpreted by some investors [51][56] - **Investor Sentiment**: Concerns about the impact of UT's announcements on MannKind's market cap and future growth potential [54][65] - **Long-term Outlook**: Despite short-term fluctuations, the company has a strong pipeline and growth drivers that could lead to significant revenue increases [61][66] Conclusion - MannKind is positioned for growth with a robust pipeline of products and strategic focus on underserved markets. The company is optimistic about upcoming trials and product launches, which could significantly impact its financial performance and market presence in the coming years.

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChris Prentiss - CFOMichael Castagna - CEORoanna Ruiz - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood morning, and welcome to the MannKind Corporation fourth quarter and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Co ...

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChris Prentiss - CFOMichael Castagna - CEORoanna Ruiz - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood morning, and welcome to the MannKind Corporation Q4 and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Corporation we ...

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Speaker4Good morning, and welcome to the MannKind Corporation fourth quarter and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Corporation website shortly after this call and for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertain ...

Q4/FY 2025 Financial Results & Business Update February 26, 2026 © Copyright 2026. All rights reserved. Mannkind Corporation. Cautionary Statement Statements in this presentation that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based up ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization ...

Conference call today at 9:00 am ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "MannKind closed 2025 with strong momentum across our commercial portfol ...

Conference call today at 9:00 am ETQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) ...

Core Insights - MannKind Corporation is scheduled to present business updates at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 11:20 a.m. ET [1] - The presentation will be available via webcast on MannKind's website, with recorded versions accessible for approximately 90 days post-conference [1] Company Overview - MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions [2] - The company specializes in treatments for cardiometabolic and orphan lung diseases, addressing serious unmet medical needs such as diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease [2] Expertise and Approach - MannKind has deep expertise in drug-device combinations, aiming to deliver therapies that integrate seamlessly into patients' daily lives [3]

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to review the f ...